Karyopharm Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 14, 2020 / 06:00PM GMT

Release Date Price: $268.2 (+3.71%)

Transcript 8-K

Eric William Joseph

JP Morgan Chase & Co, Research Division - VP & Senior Analyst

Good morning. I'm Eric Joseph, one of the senior biotech analysts at JPMorgan. And our next presenting company is Karyopharm Pharmaceuticals -- or Karyopharm Therapeutics, rather. It's my pleasure to welcome CEO, Michael Kauffman, to tell us a little bit about the company. Just as a reminder, the Q&A breakout session will be held in the Sussex Room. With that, Michael?

Michael G. Kauffman

Karyopharm Therapeutics Inc. - Co-Founder, CEO & Director

Thanks, Eric, and welcome, everybody today. It's great to be here. It's been a heck of a year for us and dive right in. As you all know, I'll make forward-looking statements. Please do review this slide and all the information in it. Now you're done reviewing. .

Karyopharm's vision is to become a leading oncology company. We are the first company that has received approval for an oral Exportin 1 inhibitor, XPOVIO, and we have a few direct competitors in development. XPOVIO, U.S. accelerated approval occurred on

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.